APA (7th ed.) Citation

IE, K., L, M., JN, P., F, A., H, B., S, L., . . . MJ, P. (2024). Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial. JCO precision oncology, 8, e2200667. https://doi.org/10.1200/PO.22.00667

Chicago Style (17th ed.) Citation

IE, Krop, et al. "Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial." JCO Precision Oncology 8 (2024): e2200667. https://doi.org/10.1200/PO.22.00667.

MLA (9th ed.) Citation

IE, Krop, et al. "Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial." JCO Precision Oncology, vol. 8, 2024, p. e2200667, https://doi.org/10.1200/PO.22.00667.